CN113521277A - Product for recovering diabetes and preparation method thereof - Google Patents
Product for recovering diabetes and preparation method thereof Download PDFInfo
- Publication number
- CN113521277A CN113521277A CN202110998432.6A CN202110998432A CN113521277A CN 113521277 A CN113521277 A CN 113521277A CN 202110998432 A CN202110998432 A CN 202110998432A CN 113521277 A CN113521277 A CN 113521277A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- parts
- extract
- product
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title abstract description 34
- 239000000284 extract Substances 0.000 claims abstract description 90
- 240000000249 Morus alba Species 0.000 claims abstract description 59
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 59
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 48
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 47
- 102000004190 Enzymes Human genes 0.000 claims abstract description 41
- 108090000790 Enzymes Proteins 0.000 claims abstract description 41
- 239000000843 powder Substances 0.000 claims abstract description 40
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 35
- 238000003756 stirring Methods 0.000 claims abstract description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 33
- 238000002156 mixing Methods 0.000 claims abstract description 32
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 31
- 229960001231 choline Drugs 0.000 claims abstract description 31
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims abstract description 31
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 31
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 27
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 27
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 27
- 229960000367 inositol Drugs 0.000 claims abstract description 27
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 27
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 27
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims abstract description 26
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims abstract description 26
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims abstract description 26
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims abstract description 26
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 26
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract description 26
- 102100036774 Afamin Human genes 0.000 claims abstract description 25
- 108010090535 alpha-albumin Proteins 0.000 claims abstract description 25
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 25
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 25
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 24
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 24
- 229960000304 folic acid Drugs 0.000 claims abstract description 24
- 235000019152 folic acid Nutrition 0.000 claims abstract description 24
- 239000011724 folic acid Substances 0.000 claims abstract description 24
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 23
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 23
- 229960002477 riboflavin Drugs 0.000 claims abstract description 23
- 229960003495 thiamine Drugs 0.000 claims abstract description 23
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 23
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 23
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 23
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 23
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 23
- 238000001694 spray drying Methods 0.000 claims abstract description 18
- 239000000047 product Substances 0.000 claims description 57
- 229940088598 enzyme Drugs 0.000 claims description 39
- 238000001035 drying Methods 0.000 claims description 31
- 239000000706 filtrate Substances 0.000 claims description 25
- 238000001976 enzyme digestion Methods 0.000 claims description 24
- 238000001914 filtration Methods 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 21
- 239000008213 purified water Substances 0.000 claims description 18
- 238000007873 sieving Methods 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 11
- 108010059892 Cellulase Proteins 0.000 claims description 10
- 102000004142 Trypsin Human genes 0.000 claims description 10
- 108090000631 Trypsin Proteins 0.000 claims description 10
- 229940106157 cellulase Drugs 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 238000002791 soaking Methods 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 10
- 239000012588 trypsin Substances 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 30
- 210000004369 blood Anatomy 0.000 abstract description 29
- 239000008280 blood Substances 0.000 abstract description 29
- 235000000346 sugar Nutrition 0.000 abstract description 24
- 208000002249 Diabetes Complications Diseases 0.000 abstract description 6
- 206010012655 Diabetic complications Diseases 0.000 abstract description 5
- 102000017011 Glycated Hemoglobin A Human genes 0.000 abstract description 5
- 108010014663 Glycated Hemoglobin A Proteins 0.000 abstract description 5
- 108010075254 C-Peptide Proteins 0.000 abstract description 4
- 238000011084 recovery Methods 0.000 abstract description 3
- 230000000291 postprandial effect Effects 0.000 abstract description 2
- 235000012054 meals Nutrition 0.000 abstract 1
- 239000000463 material Substances 0.000 description 48
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 20
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 17
- 239000003925 fat Substances 0.000 description 14
- 235000019197 fats Nutrition 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 14
- 108010088751 Albumins Proteins 0.000 description 13
- 102000009027 Albumins Human genes 0.000 description 13
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 239000008103 glucose Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102000042092 Glucose transporter family Human genes 0.000 description 10
- 108091052347 Glucose transporter family Proteins 0.000 description 10
- 108090001061 Insulin Proteins 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 9
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 9
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000032258 transport Effects 0.000 description 8
- 102000006395 Globulins Human genes 0.000 description 7
- 108010044091 Globulins Proteins 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 230000001603 reducing effect Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 210000000805 cytoplasm Anatomy 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 210000003470 mitochondria Anatomy 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 229940067606 lecithin Drugs 0.000 description 5
- 239000000787 lecithin Substances 0.000 description 5
- 235000010445 lecithin Nutrition 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- YZNNBIPIQWYLDM-HSUXUTPPSA-N Fagomine Chemical compound OC[C@H]1NCC[C@@H](O)[C@@H]1O YZNNBIPIQWYLDM-HSUXUTPPSA-N 0.000 description 3
- YZNNBIPIQWYLDM-ZLUOBGJFSA-N Fagomine Natural products OC[C@@H]1NCC[C@H](O)[C@H]1O YZNNBIPIQWYLDM-ZLUOBGJFSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- YZNNBIPIQWYLDM-UHFFFAOYSA-N L-fagomine Natural products OCC1NCCC(O)C1O YZNNBIPIQWYLDM-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000005593 Endopeptidases Human genes 0.000 description 2
- 108010059378 Endopeptidases Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000031845 Pernicious anaemia Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000004377 improving vision Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000022558 protein metabolic process Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- GWHCXVQVJPWHRF-KTKRTIGZSA-N (15Z)-tetracosenoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-KTKRTIGZSA-N 0.000 description 1
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000008720 Bone Marrow Neoplasms Diseases 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012665 Diabetic gangrene Diseases 0.000 description 1
- 206010063547 Diabetic macroangiopathy Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- XJXROGWVRIJYMO-SJDLZYGOSA-N Nervonic acid Natural products O=C(O)[C@@H](/C=C/CCCCCCCC)CCCCCCCCCCCC XJXROGWVRIJYMO-SJDLZYGOSA-N 0.000 description 1
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
- 208000002141 Pellagra Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000326 anti-hypercholesterolaemic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- GWHCXVQVJPWHRF-UHFFFAOYSA-N cis-tetracosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-UHFFFAOYSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000002016 colloidosmotic effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000000514 hepatopancreas Anatomy 0.000 description 1
- 244000059217 heterotrophic organism Species 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000005415 magnetization Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- MOYZEMOPQDTDHA-YQYZCKNZSA-N norhyoscine Chemical compound C1([C@H](C(=O)OC2C[C@@H]3N[C@@H]([C@H]4O[C@H]43)C2)CO)=CC=CC=C1 MOYZEMOPQDTDHA-YQYZCKNZSA-N 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- MOYZEMOPQDTDHA-UHFFFAOYSA-N norscopolamine Natural products C1C(C2OC22)NC2CC1OC(=O)C(CO)C1=CC=CC=C1 MOYZEMOPQDTDHA-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000002438 stress hormone Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides a product for recovering diabetes and a preparation method thereof, and relates to the technical field of diabetes recovery. The product comprises yeast, phospholipid, phosphatidylserine, choline, inositol, vitamin B1, vitamin B2, vitamin B12, folic acid, nicotinic acid, alpha-albumin, immunoglobulin, enzyme extract and mulberry leaf extract. The preparation method comprises adding yeast, phospholipid, phosphatidylserine, choline, inositol, vitamin B1, vitamin B2, vitamin B12, folic acid, nicotinic acid, alpha-albumin and immunoglobulin into folium Mori extract, stirring at 70-90r/min, spray drying at 50-70 deg.C until the water content is less than 5%, and mixing the powder with enzyme extract. The product can restore 4-6 of glycosylated hemoglobin in human body, restore normal islet C peptide, restore normal postprandial blood sugar before meal, and prevent diabetic complications with good effect.
Description
Technical Field
The invention relates to the technical field of diabetes rehabilitation, in particular to a product for recovering diabetes and a preparation method thereof.
Background
Diabetes is a group of metabolic diseases characterized by hyperglycemia. Hyperglycemia is caused by a defect in insulin secretion or an impaired biological action thereof, or both. The chronic hyperglycemia causes chronic damage and dysfunction of various tissues, particularly eyes, kidneys, hearts, blood vessels and nerves. Diabetes is divided into type 1 diabetes and type 2 diabetes, and patients with type 1 diabetes have immune system abnormality, which causes autoimmune reaction after some virus infection and damages insulin cells; type 2 diabetes results in mutations in a variety of genes, such as the insulin gene, the insulin receptor gene, the mitochondrial gene, the glucokinase gene, and the like.
The current treatment methods of diabetes comprise diet treatment, exercise treatment and drug treatment, wherein nutritional rehabilitation is the basis of treatment of various types of diabetes, and the diabetes cannot be cured by the existing drugs.
Disclosure of Invention
The invention aims to provide a product for recovering diabetes, which can provide materials and nutrition required by self-repair in a pancreas beta cell division replication cycle and when the pancreas beta cell is damaged, ensure the health of the pancreas beta cell, further ensure that the quantity and quality of insulin secreted by the pancreas beta cell are recovered to be normal, simultaneously provide materials required by glucose transporters on cell membranes, ensure that the glucose transporters transport glucose to cytoplasm, further ensure that glycosylated hemoglobin in a human body is recovered to 4-6, ensure that islet C peptide is recovered to be normal, and also can prevent diabetic complications.
The invention also aims to provide a preparation method of the product for recovering diabetes, which can promote the interaction of the components, further enhance the recovery effect of the product and enable the product to better cure the diabetes.
The technical problem to be solved by the invention is realized by adopting the following technical scheme.
The invention provides a product for recovering diabetes, which comprises the following components in parts by weight: 0.5-2 parts of yeast, 35-45 parts of phospholipid, 4-9 parts of phosphatidylserine, 1-6 parts of choline, 0.5-3 parts of inositol, 0.05-0.2 part of vitamin B1, 0.04-0.15 part of vitamin B2, 0.05-0.15 part of vitamin B12, 3-10 parts of folic acid, 1-6 parts of nicotinic acid, 15-25 parts of alpha-albumin, 18-22 parts of immunoglobulin, 0.5-1.5 parts of enzyme extract and 0.4-2 parts of mulberry leaf extract.
The invention provides a preparation method of a product for recovering diabetes, which comprises the following steps:
adding yeast, phospholipid, phosphatidyl serine, choline, inositol, vitamin B1, vitamin B2, vitamin B12, folic acid, nicotinic acid, alpha-albumin and immunoglobulin into the mulberry leaf extract, stirring and mixing for 5-20min at the stirring speed of 70-90r/min, then spray drying at 50-70 ℃, and mixing the powder with the enzyme extract for 15-30min, wherein the water content of the powder after spray drying is less than 5%.
The product for recovering diabetes and the preparation method thereof provided by the embodiment of the invention at least have the following beneficial effects:
the function principle of the product for recovering diabetes provided by the invention is as follows: the health of pancreatic beta cells is guaranteed by providing materials and nutrients required by self-repair in the division and replication cycle of the pancreatic beta cells and during damage, so that the quantity and quality of insulin secreted by the pancreatic beta cells are normal; simultaneously, materials required by glucose transporters on cell membranes are provided, and the glucose transporters are ensured to transport glucose to cytoplasm; and materials required by human cell mitochondria can be provided, and the health of mitochondria is guaranteed, so that the ability of metabolizing glucose, fat and amino acid is recovered to be normal, further, the glycosylated hemoglobin in a human body is recovered to be 4-6, the islet C peptide is recovered to be normal, and the diabetic complication is prevented.
In the embodiment, through the matching use of phospholipid, phosphatidylserine and choline, materials and nutrients required by self-repair in the division and replication cycle and in the damaged pancreatic beta cells can be provided, and the health of the pancreatic beta cells is ensured, so that the quantity and quality of insulin secreted by the pancreatic beta cells are normal; simultaneously, materials required by glucose transporters on cell membranes are provided, and the glucose transporters are ensured to transport glucose to cytoplasm; and the material required by human cell mitochondria can be provided, and the health of mitochondria is guaranteed, so that the ability of metabolizing glucose, fat and amino acid is recovered to be normal. The yeast, the vitamin B1, the vitamin B12, the folic acid, the nicotinic acid, the mulberry leaf extract and the enzyme extract are used in combination, all the components have the function of regulating blood sugar, the enzyme extract can accelerate protein metabolism in vivo, and the function of regulating blood sugar can be further enhanced when the enzyme extract is used in combination, so that the blood sugar in vivo is recovered to be normal. In addition, inositol, choline, vitamin B2 and the enzyme extract are used in combination, so that cholesterol in the body can be reduced, fat metabolism is facilitated, and the effect of preventing diabetic complications is achieved. Alpha-albumin and immunoglobulin are main proteins in human plasma, maintain the normal value of albumin/globulin (A/G), play a key role in regulating blood sugar, and can further restore the normal blood sugar in vivo by supplementing the alpha-albumin and immunoglobulin in vivo. The components can better play a role in vivo due to proper proportion, and the mutual synergistic promotion of the functions can further enhance the rehabilitation effect of the product, thereby promoting the rehabilitation of diabetes.
The preparation method of the invention can promote the interaction of the components, thereby enhancing the rehabilitation effect of the product and leading the product to better cure the diabetes.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
It should be noted that the embodiments and features of the embodiments in the present application may be combined with each other without conflict. The present invention will be described in detail below with reference to specific examples.
A product for recovering diabetes comprises the following components in parts by weight: 0.5-2 parts of yeast, 35-45 parts of phospholipid, 4-9 parts of phosphatidylserine, 1-6 parts of choline, 0.5-3 parts of inositol, 0.05-0.2 part of vitamin B1, 0.04-0.15 part of vitamin B2, 0.05-0.15 part of vitamin B12, 3-10 parts of folic acid, 1-6 parts of nicotinic acid, 15-25 parts of alpha-albumin, 18-22 parts of immunoglobulin, 0.5-1.5 parts of enzyme extract and 0.4-2 parts of mulberry leaf extract.
Yeast is a natural starter. The yeast can decompose macromolecular substances into small molecular substances which are easy to be utilized by cell metabolism, and belongs to heterotrophic organisms. The yeast is facultative anaerobe, which decomposes sugar into carbon dioxide and water under aerobic condition and the yeast grows faster; in the absence of oxygen, yeast break down sugars into alcohol and carbon dioxide.
Phospholipids, also known as phospholipids or phospholipids, are lipids containing phosphoric acid and belong to complex lipids. Phospholipids are the main components constituting biological membranes, and are divided into two main categories, namely glycerophospholipids and sphingomyelins, which are respectively composed of glycerol and sphingosine. Phospholipids are amphiphilic molecules with a hydrophilic nitrogen or phosphorus containing head at one end and a long hydrophobic (oleophilic) alkyl chain at the other end, the hydrophilic head of the phospholipid being located on the membrane surface and the hydrophobic tail being located inside the membrane in biological membranes. Phospholipids often form together with other molecules such as proteins, glycolipids, cholesterol, etc., a phospholipid bilayer, i.e., the structure of the cell membrane. The phospholipid has the physiological functions of regulating blood fat, improving memory, protecting liver, strengthening brain, improving intelligence, delaying aging, etc. In particular, lecithin has the functions of emulsifying and decomposing grease, improving blood circulation, improving serum lipid, removing peroxide, reducing the content of cholesterol and neutral fat in blood, reducing the detention time of fat on the inner wall of a blood vessel, promoting the dissipation of atherosclerotic plaque, and preventing the damage of intima of the blood vessel caused by cholesterol. However, insufficient lecithin causes a reduction in pancreatic function, and fails to secrete sufficient insulin, and thus glucose in blood cannot be efficiently transported to cells, which is one of the basic causes of diabetes. Lecithin is more effective for diabetic gangrene and arteriosclerosis and other complications. Phospholipids may also be involved in the transport of fat and cholesterol, and their low plasma phospholipids increase the cholesterol/lecithin ratio and cause cholesterol deposits which may lead to atherosclerosis, thus having an anti-hypercholesterolemic effect.
Phosphatidylserine, also known as complex nervonic acid, is an active substance of cell membranes, especially present in brain cells. The functional components mainly improve nerve cell function, regulate the conduction of nerve pulse and enhance brain memory function, and the lipophilic components can quickly enter the brain through a blood brain barrier after being absorbed due to strong lipophilicity, thereby playing the roles of relieving blood vessel smooth muscle cells and increasing blood supply of the brain. Phosphatidylserine (PS) can remarkably reduce the level of excessive stress hormone in the body of a person with work stress, further reduce pressure and relieve brain fatigue, can also act on the level of neurotransmitter which influences mood in the brain, can promote concentration, improve alertness and memory, and help to relieve bad mood (such as depression, depression and the like). Phosphatidylserine is one of the main components of brain nerves, can nourish and activate the activity of various enzymes in the brain, can delay the reduction process of neurotransmitter, and is helpful for repairing and updating damaged cells of the brain and removing harmful substances.
Choline is a constituent of all biological membranes and is a precursor of acetylcholine in cholinergic neurons, of the formula C5H14ON+. The concentration of choline in cytoplasm is 8-25 micromoles/liter, and the concentration of choline in brain is 25-50 nanomoles/liter. The acquisition of choline in the body takes place either via the liver, eggs and the like (mainly in the form of Phosphatidylcholine (PC) and lecithin), or from endogenously synthesized PC (via a continuous methylation process of Phosphatidylethanolamine (PE)). Choline is important in cell membrane structure and lipoprotein composition. Choline has affinity for fat, and can promote the transport of fat in phospholipid form from liver through blood or improve the utilization of fatty acid in liver, and prevent fatAbnormal accumulation in the liver. The choline and the phospholipid have good emulsifying property, can prevent the cholesterol from depositing on the inner wall of a blood vessel and clear partial deposits, and simultaneously improve the absorption and utilization of fat, thereby having the effect of preventing cardiovascular diseases.
Inositol, also known as inositol, exists in nature in a plurality of cis and trans isomers, and the naturally occurring isomer is cis-1, 2,3, 5-trans-4, 6-inositol. Inositol has effect of reducing cholesterol; promoting the growth of healthy hair, and preventing alopecia; preventing eczema; help in redistribution (redistribution) of body fat; a sedative effect; combining inositol and bilobatin to obtain ovoflavin; supplying nutrition to brain cells.
The nutritional effect of vitamin B1 is to allow sugar to be further metabolized in vivo, and also to help fat and carbohydrate as another intermediate metabolite, a-ketoglutaric acid, to promote gastric emptying and digestion. The vitamin B2 has the following functions: promoting development and cell regeneration; promoting normal growth of skin, nail and hair; help to eliminate inflammation in the oral cavity, lips and tongue; improving vision and relieving eye fatigue; and other substances to assist in the metabolism of carbohydrates, fats, and proteins. Since vitamin B12 is absorbed in the stomach, it needs to be combined with "intrinsic factors" secreted from the gastric mucosa to act, and thus, when some diseases such as chronic diarrhea and atrophic gastritis affect secretion of the "intrinsic factors", vitamin B12 is easily deficient, resulting in pernicious anemia. Vitamin B12 is an essential substance for promoting growth, maintaining health of nerve tissues and forming normal erythrocytes (erythrocytes), and particularly, when nucleated erythrocytes (precursors of erythrocytes) are formed in bone marrow, vitamin B12 is required to provide methyl groups to synthesize deoxyribonucleic acid, otherwise, the cells cannot divide and can only continue to synthesize proteins continuously, so that the erythrocytes become bigger and bigger, and become megaerythrocytes to form pernicious anemia. Another physiological function of vitamin B12 is to maintain normal function of the nervous system and promote the synthesis of myelin.
Folic acid is a water-soluble vitamin with the molecular formula of C19H19N7O6The parent compound is prepared fromPteridine, p-aminobenzoic acid and glutamic acid 3. Folic acid plays an important role in protein synthesis, cell division and growth, and has a promoting effect on the formation of normal red blood cells. The deficiency can cause the reduction of hemoglobin production in erythrocytes and the obstruction of cell maturation, resulting in megaloblastic anemia. Nicotinic acid belongs to vitamin B group, also called nicotinic acid, vitamin B3, pellagra resisting factor, and the molecular formula is C6H5NO2Pyridine-3-formic acid, has good thermal stability and can be sublimed. Nicotinic acid can affect the hematopoietic process, promote iron absorption and hematopoiesis; maintaining normal function of the skin and secretion of digestive glands; improving excitability of central nerve, cardiovascular system, reticuloendothelial system and endocrine function.
Alpha-albumin, also known as alpha-lactalbumin, is the most important protein in human plasma and maintains body nutrition and osmotic pressure. Albumin has important physiological functions in the body: the albumin can maintain the plasma colloid osmotic pressure constant; albumin belongs to non-specific transport protein, and can be reversibly combined with a plurality of insoluble small molecular organic matters and inorganic ions in vivo to form a soluble compound, so that the albumin becomes a transport form of the substances in blood circulation; the albumin can ensure the communication between intracellular fluid, extracellular fluid and interstitial fluid; albumin plays a colloid-protective and stabilizing role in globulin; albumin is an important nutrient in the human body; the albumin has viscosity and colloid property, and can be automatically combined with heavy metal ions when meeting the heavy metal ions in a human body, thereby playing a role in detoxification.
Immunoglobulin (Ig) refers to a globulin having the activity or chemical structure of an antibody (Ab) that is similar to an antibody molecule. Immunoglobulins are tetrapeptide chain structures made up of two identical light chains and two identical heavy chains joined by interchain disulfide bonds. Immunoglobulins can be classified into antibodies, which are mainly present in serum, but also in other body fluids and other exudates, and membrane immunoglobulins, which have the main function of specifically binding to antigens; the membrane immunoglobulin is an antigen receptor on B cell membrane, can specifically recognize antigen molecules, can directly play a role after combining an antibody and an antigen in vivo, and can generate the phenomena of agglutination, precipitation and the like after combining the antibody and the antigen in vitro.
Globulin is a serum protein existing in the human body and has an immunological function, and is also called immunoglobulin. Albumin/globulin (A/G) is of clinical importance: the normal value of A/G is 1.5 to (2.5: 1). The A/G increase may be an increase in albumin due to a disease of nutrient excess, or a deficiency in immunoglobulin (antibody). The A/G reduction may be: 1. due to the reduction of albumin: a reduction in synthesis capacity; increased extravascular extravasation, renal cirrhosis, protein exudative gastrointestinal inflammation, cirrhosis, burns, malignant tumors, and the like; 2. due to the increase of globulin: increased antibodies caused by infectious diseases; bone marrow tumor-induced increase in abnormal proteins.
The active ingredients of the enzyme extract and the yeast extract are protease, and the protease is a general name of enzymes for hydrolyzing protein peptide chains. The polypeptide is divided into endopeptidase and terminal peptidase according to the mode of degrading polypeptide, the endopeptidase can cut off the polypeptide chain with large molecular weight from the middle to form the prion and peptone with smaller molecular weight; the latter are in turn classified as carboxypeptidases and aminopeptidases, which hydrolyze the peptide chain one by one from the free carboxyl terminus or the free amino terminus of the polypeptide to amino acids, respectively.
The mulberry leaf extract contains deoxynojirimycin as an active ingredient and has the effects of regulating blood sugar, dispelling wind and heat, clearing away the lung-heat, moistening dryness, clearing liver and improving vision. The mechanism of blood glucose lowering: firstly, alkaloid DNJ (1-deoxynojirimycin) has an inhibitory effect on the activity of disaccharide degrading enzymes, so that the absorption of disaccharide by small intestine is inhibited, and the high peak value of postprandial blood sugar is reduced (Kimura, 1995); secondly, the beta cells are promoted to secrete insulin through mulberry leaf alkaloid fagomine and mulberry leaf polysaccharide, and the insulin can promote the utilization of cells on sugar, the synthesis of hepatic glycogen and the improvement of glycometabolism, so that the effect of reducing blood sugar is finally achieved. Polyhydroxy norscopolamine in mulberry leaf extracts has a strong glycosidase inhibitory effect (Asano et al, 1994); N-Me-DNJ, GAL-DNJ and fagomine can remarkably reduce the blood sugar level, wherein the GAL-DNJ and the fagomine have the strongest blood sugar reducing effect.
In the embodiment, through the matching use of phospholipid, phosphatidylserine and choline, materials and nutrients required by self-repair in the division and replication cycle and in the damaged pancreatic beta cells can be provided, and the health of the pancreatic beta cells is ensured, so that the quantity and quality of insulin secreted by the pancreatic beta cells are normal; simultaneously, materials required by glucose transporters on cell membranes are provided, and the glucose transporters are ensured to transport glucose to cytoplasm; and the material required by human cell mitochondria can be provided, and the health of mitochondria is guaranteed, so that the ability of metabolizing glucose, fat and amino acid is recovered to be normal. The yeast, the vitamin B1, the vitamin B12, the folic acid, the nicotinic acid, the mulberry leaf extract and the enzyme extract are used in combination, all the components have the function of regulating blood sugar, the enzyme extract can accelerate protein metabolism in vivo, and the function of regulating blood sugar can be further enhanced when the enzyme extract is used in combination, so that the blood sugar in vivo is recovered to be normal. In addition, inositol, choline, vitamin B2 and the enzyme extract are used in combination, so that cholesterol in the body can be reduced, fat metabolism is facilitated, and the effect of preventing diabetic complications is achieved. Alpha-albumin and immunoglobulin are main proteins in human plasma, maintain the normal value of albumin/globulin (A/G), play a key role in regulating blood sugar, and can further restore the normal blood sugar in vivo by supplementing the alpha-albumin and immunoglobulin in vivo. The components can better play a role in vivo due to proper proportion, and the mutual synergistic promotion of the functions can further enhance the rehabilitation effect of the product.
A preparation method of a product for recovering diabetes comprises the following steps:
adding yeast, phospholipid, phosphatidyl serine, choline, inositol, vitamin B1, vitamin B2, vitamin B12, folic acid, nicotinic acid, alpha-albumin and immunoglobulin into the mulberry leaf extract, stirring and mixing for 5-20min at the stirring speed of 70-90r/min, then spray drying at 50-70 ℃, and then carrying out magnetic treatment on the material powder and the enzyme extract, sieving the material powder after the magnetic treatment, and sieving the material powder with 15-25 meshes, and then mixing the material powder and the enzyme extract for 15-30 min.
The preparation process of the ferment extract comprises the following steps: drying crops at 45-60 ℃ for 30-40min, crushing the crops, enabling the crushed crops to have the grain size of 1-15mm, sterilizing for 10-20min, mixing the crushed crops with trypsin and cellulase, carrying out enzyme digestion at 30-38 ℃ for 15-25min, stirring at the stirring speed of 75-85r/min during the enzyme digestion process, filtering after enzyme digestion, drying the filtrate at-10 ℃ to-50 ℃ for 24-50h, and enabling the vacuum degree during drying to be 2-5 MPa.
The preparation process of the mulberry leaf extract comprises the following steps: adding purified water into folium Mori, soaking for 10-20min, decocting at 95-105 deg.C for 38-50min, filtering, concentrating the filtrate under 0.5-2MPa at 75-85 deg.C, and concentrating to obtain filtrate with solid-to-liquid ratio of 1: (0.8-1.2), preferably the solid-to-liquid ratio is 1: 1.
in this example, the mass of purified water was 1.5-3 times that of mulberry leaves. Therefore, the content of effective components in the obtained mulberry leaf extract is higher, and the blood sugar regulating effect of the mulberry leaf extract is better.
In this embodiment, the other components except the enzyme extract are added to the mulberry leaf extract, and the mixture is mixed for 5-20min at a stirring speed of 70-90r/min, so that the components can be mixed more uniformly at the stirring speed, the effective components among the components can collide with each other by stirring, the movement of the effective components can be accelerated, the mixing speed among the components is accelerated, and the uniformity of the solution is better. And then spray drying at 50-70 ℃, wherein the loss of vitamins can be reduced by drying at the temperature, the activity of protein can also be ensured, and better feed liquid can be dried by adopting spray drying, so that the drying effect of the feed powder is better. The material powder and the ferment extract are mixed and are subjected to over-magnetization treatment, wherein the over-magnetization is mainly used for removing metal substances in the material, and the phenomenon that the metal is excessively accumulated in a human body in the using process and then the human body is damaged is avoided. Sieving can filter out large granular substances, and when the material powder is mixed with the enzyme extract, the particle size of the material is close, so that the mixing effect between the materials is better, and the mixing time can ensure that the materials are mixed uniformly, so that the mixing time is 15-30 min.
In the process for preparing the enzyme extract of this embodiment, the crops are fruits, vegetables and grains. The method comprises the steps of drying crops, cleaning the crops before drying, removing water on the surfaces of the crops through drying, and evaporating water contained in the crops to reduce the water content so as to improve the active ingredients in the crops. Drying at 45-60 deg.C for 30-40min can ensure good drying effect of crops, and avoid high water content of crops and poor pulverizing effect during pulverizing. The grain size after being crushed is 1-15mm, which is convenient for subsequent fermentation, and particularly, the crops are more fully contacted with trypsin and cellulase. The sterilization is carried out by adopting ultraviolet rays, so that bacteria in crops can be killed, and the influence of the bacteria on the subsequent fermentation process is avoided. And (3) carrying out enzyme digestion on the crushed and sterilized material, wherein the enzyme digestion is mainly used for increasing the content of active ingredients in the enzyme extract, and the enzyme digestion is carried out for 15-25min at the temperature of 30-38 ℃, so that the enzyme digestion effect is better, and the content of the active ingredients is higher. Filtering after enzyme digestion, wherein the aperture of a filter membrane for filtering is 4mm, drying the filtrate at the temperature of minus 10 ℃ to minus 50 ℃ for 24-50h, and drying at the temperature so as to ensure the activity of protease in the enzyme extract and avoid the inactivation of the protease at high temperature.
In detail, the preparation process of the enzyme extract comprises 2-10 parts of trypsin and 3-12 parts of cellulase.
In the preparation process of the mulberry leaf extract, before the mulberry leaves are used, the mulberry leaves need to be selected, cleaned and sliced, the mulberry leaves with good quality are selected, so that the effective components in the mulberry leaf extract can be increased, impurities remained on the mulberry leaves can be removed through cleaning, the quality of the mulberry leaf extract is improved, the slicing is to reduce the area of the mulberry leaves, the purified water is used for better soaking the mulberry leaves, and the softening speed of the mulberry leaves is higher. The soaking of the mulberry leaves in purified water is used for softening the mulberry leaves, so that the effective components in the mulberry leaves can be extracted quickly when the mulberry leaves are subsequently steamed and boiled, and the best effect is achieved after the mulberry leaves are soaked for 10-20 min. Steaming and boiling at 95-105 deg.C for 38-50min, the deoxynojirimycin can be effectively extracted when folium Mori is steamed, and simultaneously, extraction at the temperature can not only accelerate the extraction rate of deoxynojirimycin, but also make the precipitation degree of deoxynojirimycin in folium Mori better. And (2) filtering after cooking, wherein the aperture of a filtering membrane for filtering is 4mm, so that filter residues can be removed, then concentrating is carried out, the pressure during concentration is 0.5-2MPa, the temperature is 75-85 ℃, and the solid-to-liquid ratio in filtrate after concentration is 1: (0.8-1.2), concentration is carried out under the condition, the density of the deoxynojirimycin in the filtrate can be increased under the condition that the deoxynojirimycin is not damaged, and the effect of regulating blood sugar is better when the deoxynojirimycin is used.
The features and properties of the present invention are described in further detail below with reference to examples.
Example 1
A product for recovering diabetes comprises the following components:
1g yeast, 40g phospholipids, 6g phosphatidylserine, 3g choline, 1g inositol, 0.1g vitamin B1, 0.1g vitamin B2, 0.1g vitamin B12, 5g folic acid, 3g niacin, 20g alpha-albumin, 20g immunoglobulin, 1g ferment extract and 1g mulberry leaf extract.
A preparation method of a product for recovering diabetes comprises the following steps:
adding yeast, phospholipid, phosphatidylserine, choline, inositol, vitamin B1, vitamin B2, vitamin B12, folic acid, nicotinic acid, alpha-albumin and immunoglobulin into the mulberry leaf extract, stirring and mixing for 10min at the stirring speed of 80r/min, then carrying out spray drying at 60 ℃, wherein the water content of the material powder after spray drying is less than 5%, carrying out magnetic treatment on the material powder and the enzyme extract, sieving the material powder after the magnetic treatment, sieving the material powder with a sieve mesh number of 20 meshes, and then mixing the material powder and the enzyme extract for 20min to obtain a finished product.
The preparation process of the ferment extract comprises the following steps: drying crops at 50 ℃ for 35min, crushing the crops, grinding the crushed crops to have the particle size of 10mm, sterilizing the crushed crops for 15min, mixing the crushed crops with 5g of trypsin and 5g of cellulase, carrying out enzyme digestion at 35 ℃ for 20min, stirring the mixture during the enzyme digestion process at the stirring speed of 80r/min, filtering the mixture after the enzyme digestion, drying the filtrate at-20 ℃ for 36h, and ensuring the vacuum degree during the drying to be 4 MPa.
The preparation process of the mulberry leaf extract comprises the following steps: adding purified water into folium Mori, soaking for 15min, decocting at 100 deg.C for 40min, filtering, concentrating the filtrate at 80 deg.C under 0.8MPa to obtain concentrated solution with solid-to-liquid ratio of 1: 1.
the mass of purified water in this example was 2 times that of mulberry leaves.
Example 2
A product for recovering diabetes comprises the following components:
0.5g yeast, 35g phospholipids, 4g phosphatidylserine, 1g choline, 0.5g inositol, 0.05g vitamin B1, 0.04g vitamin B2, 0.05g vitamin B12, 3g folic acid, 1g niacin, 15g alpha-albumin, 18g immunoglobulin, 0.5g ferment extract and 0.4g mulberry leaf extract.
A preparation method of a product for recovering diabetes comprises the following steps:
adding yeast, phospholipid, phosphatidylserine, choline, inositol, vitamin B1, vitamin B2, vitamin B12, folic acid, nicotinic acid, alpha-albumin and immunoglobulin into the mulberry leaf extract, stirring and mixing for 5min at the stirring speed of 70r/min, then carrying out spray drying at 50 ℃, wherein the water content of the material powder after spray drying is less than 5%, carrying out magnetic treatment on the material powder and the enzyme extract, sieving the material powder after the magnetic treatment, sieving the material powder with a sieve mesh number of 15 meshes, and then mixing the material powder and the enzyme extract for 15min to obtain a finished product.
The preparation process of the ferment extract comprises the following steps: drying crops at 45 ℃ for 30min, crushing the crops, grinding the crushed crops to have the grain size of 1mm, sterilizing the crushed crops for 10min, mixing the crushed crops with 2g of trypsin and 3g of cellulase, carrying out enzyme digestion at 30 ℃ for 15min, stirring the mixture during the enzyme digestion process at the stirring speed of 75r/min, filtering the mixture after the enzyme digestion, drying the filtrate at-10 ℃ for 24h, and ensuring the vacuum degree during the drying to be 2 MPa.
The preparation process of the mulberry leaf extract comprises the following steps: adding purified water into folium Mori, soaking for 10min, decocting at 95 deg.C for 38min, filtering, concentrating the filtrate at 75 deg.C under 0.5MPa to obtain concentrated solution with solid-to-liquid ratio of 1: 0.8.
the mass of purified water in this example was 1.5 times that of mulberry leaves.
Example 3
A product for recovering diabetes comprises the following components:
2g yeast, 45g phospholipids, 9g phosphatidylserine, 6g choline, 3g inositol, 0.2g vitamin B1, 0.15g vitamin B2, 0.15g vitamin B12, 10g folic acid, 6g niacin, 25g alpha-albumin, 22g immunoglobulin, 1.5g ferment extract and 2g mulberry leaf extract.
A preparation method of a product for recovering diabetes comprises the following steps:
adding yeast, phospholipid, phosphatidylserine, choline, inositol, vitamin B1, vitamin B2, vitamin B12, folic acid, nicotinic acid, alpha-albumin and immunoglobulin into the mulberry leaf extract, stirring and mixing for 20min at the stirring speed of 90r/min, then carrying out spray drying at 70 ℃, wherein the water content of the material powder after spray drying is less than 5%, carrying out magnetic treatment on the material powder and the enzyme extract, sieving the material powder after the magnetic treatment, sieving the material powder with a sieve mesh number of 25 meshes, and then mixing the material powder and the enzyme extract for 30min to obtain a finished product.
The preparation process of the ferment extract comprises the following steps: drying crops at 60 ℃ for 40min, crushing the crops, grinding the crushed crops to have the grain size of 15mm, sterilizing the crushed crops for 20min, mixing the crushed crops with 10g of trypsin and 12g of cellulase, carrying out enzyme digestion at 38 ℃ for 25min, stirring the mixture during the enzyme digestion process at the stirring speed of 85r/min, filtering the mixture after the enzyme digestion, drying the filtrate at-50 ℃ for 50h, and ensuring the vacuum degree during the drying to be 5 MPa.
The preparation process of the mulberry leaf extract comprises the following steps: adding purified water into folium Mori, soaking for 20min, decocting at 105 deg.C for 50min, filtering, concentrating the filtrate at 85 deg.C under 2MPa to obtain concentrated filtrate with solid-to-liquid ratio of 1: 1.2.
the mass of purified water in this example was 3 times that of mulberry leaves.
Example 4
A product for recovering diabetes comprises the following components:
1.5g yeast, 38g phospholipids, 7g phosphatidylserine, 2g choline, 2g inositol, 0.15g vitamin B1, 0.08g vitamin B2, 0.09g vitamin B12, 8g folic acid, 2g niacin, 18g alpha-albumin, 21g immunoglobulin, 1.2g ferment extract and 1.5g mulberry leaf extract.
A preparation method of a product for recovering diabetes comprises the following steps:
adding yeast, phospholipid, phosphatidylserine, choline, inositol, vitamin B1, vitamin B2, vitamin B12, folic acid, nicotinic acid, alpha-albumin and immunoglobulin into the mulberry leaf extract, stirring and mixing for 10min at the stirring speed of 75r/min, then carrying out spray drying at 55 ℃, carrying out magnetic treatment on the material powder and the enzyme extract, carrying out sieving after the magnetization, carrying out sieving with the sieve mesh number of 18 meshes, and then mixing the material powder and the enzyme extract for 25min to obtain a finished product.
The preparation process of the ferment extract comprises the following steps: drying crops at 55 ℃ for 32min, crushing the crops, grinding the crushed crops to obtain a particle size of 5mm, sterilizing the crushed crops for 12min, mixing the sterilized crops with 4g of trypsin and 6g of cellulase, carrying out enzyme digestion at 32 ℃ for 18min, stirring the mixture during the enzyme digestion process at a stirring speed of 78r/min, filtering the mixture after the enzyme digestion, drying the filtrate at-30 ℃ for 48h, and controlling the vacuum degree during the drying to be 2.8 MPa.
The preparation process of the mulberry leaf extract comprises the following steps: adding purified water into folium Mori, soaking for 12min, decocting at 98 deg.C for 45min, filtering, concentrating the filtrate at a concentration pressure of 1MPa and a temperature of 78 deg.C, and concentrating to obtain filtrate with a solid-to-liquid ratio of 1: 0.9.
the mass of purified water in this example was 1.8 times that of mulberry leaves.
Example 5
A product for recovering diabetes comprises the following components:
1.8g yeast, 41g phospholipids, 5.5g phosphatidylserine, 3.5g choline, 2.5g inositol, 0.12g vitamin B1, 0.11g vitamin B2, 0.13g vitamin B12, 7g folic acid, 4g niacin, 17g alpha-albumin, 19g immunoglobulin, 1.2g enzyme extract and 1.3g mulberry leaf extract.
A preparation method of a product for recovering diabetes comprises the following steps:
adding yeast, phospholipid, phosphatidylserine, choline, inositol, vitamin B1, vitamin B2, vitamin B12, folic acid, nicotinic acid, alpha-albumin and immunoglobulin into the mulberry leaf extract, stirring and mixing for 17min at the stirring speed of 85r/min, then carrying out spray drying at 65 ℃, wherein the water content of the material powder after spray drying is less than 5%, carrying out magnetic treatment on the material powder and the enzyme extract, sieving the material powder after the magnetic treatment, sieving the material powder with 22 meshes, and then mixing the material powder and the enzyme extract for 23min to obtain a finished product.
The preparation process of the ferment extract comprises the following steps: drying crops at 56 deg.C for 38min, pulverizing crops to particle size of 12mm, sterilizing for 13min, mixing with 6g trypsin and 7g cellulase, performing enzyme digestion at 31 deg.C for 22min while stirring at 81r/min, filtering, drying the filtrate at-40 deg.C for 30h, and vacuum degree of 4.5 MPa.
The preparation process of the mulberry leaf extract comprises the following steps: adding purified water into folium Mori, soaking for 16min, decocting at 101 deg.C for 41min, filtering, concentrating the filtrate at 1.2MPa and 77 deg.C, and concentrating to obtain filtrate with solid-to-liquid ratio of 1: 1.1.
the mass of purified water in this example was 1.8 times that of mulberry leaves.
Example 6
A product for recovering diabetes comprises the following components:
1.3g yeast, 37g phospholipids, 7g phosphatidylserine, 5g choline, 0.8g inositol, 0.09g vitamin B1, 0.09g vitamin B2, 0.09g vitamin B12, 6.8g folic acid, 2.8g nicotinic acid, 24g alpha-albumin, 19g immunoglobulin, 1.2g ferment extract and 0.9g mulberry leaf extract.
A preparation method of a product for recovering diabetes comprises the following steps:
adding yeast, phospholipid, phosphatidylserine, choline, inositol, vitamin B1, vitamin B2, vitamin B12, folic acid, nicotinic acid, alpha-albumin and immunoglobulin into the mulberry leaf extract, stirring and mixing for 9min at the stirring speed of 72r/min, then carrying out spray drying at 51 ℃, enabling the water content of the material powder after spray drying to be less than 5%, and then mixing the material powder with the enzyme extract for 16min to obtain a finished product.
The preparation process of the ferment extract comprises the following steps: drying crops at 58 deg.C for 38min, sterilizing for 18min, mixing with 8g trypsin and 9g cellulase, performing enzyme digestion at 37 deg.C for 23min, filtering, and drying the filtrate at-15 deg.C for 35 h.
The preparation process of the mulberry leaf extract comprises the following steps: adding purified water into folium Mori, soaking for 18min, decocting at 102 deg.C for 42min, filtering, concentrating the filtrate under 1.2MPa at 82 deg.C, and concentrating to obtain filtrate with solid-to-liquid ratio of 1: 0.95.
the mass of purified water in this example was 2.2 times that of mulberry leaves.
1. Toxicity test
Selecting 70 mice with half male and female bodies and weight of 250-300 g, dividing into 7 groups, and dividing each group into 10 mice, wherein one group of mice is a blank control group, the rest six mice are respectively taken with the product prepared by the embodiment of the invention every morning and evening, fasting is performed within 15h before and 5h after administration, but water is not prohibited, the administration is performed for 60 days in a connecting way, the growth and development, behavior and activity, water intake during eating, respiration, body temperature, hematuria routine, liver and kidney functions and other reactions of animals are observed, after the last administration, blood is taken for assay, the animals are dissected and observed with naked eyes, and pathological section examination is performed on main organs such as heart, liver, spleen, lung, kidney and the like.
The test results are as follows: after the medicine is taken for 60 days, the observation indexes of the experimental animals are not changed abnormally or the animals die, and the observation indexes are not obviously different from those of the control group by visual observation, and the animals are not changed abnormally and pathologically after being dissected and examined by the histology of organs. Therefore, the product prepared by the invention has little toxicity.
2. Clinical treatment trial
Selecting 60 people with clinical manifestations of hyperglycemia and hypercholesterolemia, then dividing the clinical manifestations into 6 groups, wherein 10 people in each group and 6 groups respectively correspond to the products in the embodiments 1-6, taking the products in the morning and at night every day, and after taking the products for 60 days, respectively detecting the average blood glucose content before treatment and the average blood glucose content after treatment in each group, wherein the specific data are as follows:
TABLE 1 results table
As can be seen from Table 1, examples 1 to 6 all had the effect of reducing blood glucose levels. Compared with the examples 2-6, the blood sugar reducing effect of the example 1 is better, and compared with the examples 2-5, the product obtained by the example 1 has better effect of treating diabetes under the operating conditions and the mixture ratio of the components of the example 1; compared with the example 6, the product obtained by the method has better effect of treating the diabetes under the conditions of increased operation steps, operation conditions and the proportion of the components. The product of the invention can not only enable the blood sugar content of a tester to be recovered to normal, but also enable the glycosylated hemoglobin in a human body to be recovered to normal, so that the product obtained by the invention can effectively cure diabetes and has good curing effect.
In summary, the product for diabetes rehabilitation and the preparation method thereof provided by the embodiment of the invention can provide materials and nutrients required for self-repair in the division and replication cycle of pancreatic beta cells and during damage, ensure the health of pancreatic beta cells, thus the quantity and quality of insulin secreted by pancreatic beta cells are recovered to be normal, and simultaneously provide materials required for glucose transporters on cell membranes, so that the glucose transporters are ensured to transport glucose to cytoplasm, further the glycosylated hemoglobin in vivo is recovered to 4-6, the pancreatic C peptide is recovered to be normal, and diabetes complications can be prevented. The invention provides a preparation method of a product for recovering diabetes, which can promote the interaction of all components, further enhance the recovery effect of the product and enable the product to better cure the diabetes.
The embodiments described above are some, but not all embodiments of the invention. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention as claimed, but is merely representative of selected embodiments of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Claims (10)
1. The product for recovering diabetes is characterized by comprising the following components in parts by weight: 0.5-2 parts of yeast, 35-45 parts of phospholipid, 4-9 parts of phosphatidylserine, 1-6 parts of choline, 0.5-3 parts of inositol, 0.05-0.2 part of vitamin B1, 0.04-0.15 part of vitamin B2, 0.05-0.15 part of vitamin B12, 3-10 parts of folic acid, 1-6 parts of nicotinic acid, 15-25 parts of alpha-albumin, 18-22 parts of immunoglobulin, 0.5-1.5 parts of enzyme extract and 0.4-2 parts of mulberry leaf extract.
2. A method of preparing the product of claim 1, comprising the steps of: adding yeast, phospholipid, phosphatidylserine, choline, inositol, vitamin B1, vitamin B2, vitamin B12, folic acid, nicotinic acid, alpha-albumin and immunoglobulin into the mulberry leaf extract, stirring and mixing for 5-20min at the stirring speed of 70-90r/min, then carrying out spray drying at 50-70 ℃, enabling the water content of the spray-dried powder to be less than 5%, and then mixing the powder and the enzyme extract for 15-30 min.
3. The method of claim 2, wherein the ferment extract is prepared by a process comprising: drying crops at 45-60 deg.C for 30-40min, sterilizing for 10-20min, mixing with trypsin and cellulase, performing enzyme digestion at 30-38 deg.C for 15-25min, filtering, and drying the filtrate at-10 deg.C to-50 deg.C for 24-50 h.
4. The method of claim 3, further comprising pulverizing the agricultural product to a particle size of 1-15mm before the sterilization process.
5. The method for preparing the product according to claim 3, wherein stirring is performed at a speed of 75-85r/min during enzyme digestion.
6. The method for producing a product according to claim 3, wherein the degree of vacuum at the time of drying is 2 to 5 MPa.
7. The method for preparing a product according to claim 2, wherein the mulberry leaf extract is prepared by the following steps: adding purified water into folium Mori, soaking for 10-20min, decocting at 95-105 deg.C for 38-50min, filtering, concentrating the filtrate, and concentrating to obtain filtrate with solid-to-liquid ratio of 1: (0.8-1.2).
8. The method for preparing a product according to claim 7, wherein the purified water has a mass 1.5-3 times that of the mulberry leaves.
9. The method for producing a product according to claim 7, wherein the pressure at the time of concentration is 0.5 to 2MPa and the temperature is 75 to 85 ℃.
10. The method for preparing the product according to claim 2, wherein before mixing the powder with the enzyme extract, the method further comprises the steps of performing magnetic treatment on the powder and the enzyme extract, sieving the powder after the magnetic treatment, and sieving the powder with 15-25 meshes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110998432.6A CN113521277A (en) | 2021-08-27 | 2021-08-27 | Product for recovering diabetes and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110998432.6A CN113521277A (en) | 2021-08-27 | 2021-08-27 | Product for recovering diabetes and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113521277A true CN113521277A (en) | 2021-10-22 |
Family
ID=78092215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110998432.6A Pending CN113521277A (en) | 2021-08-27 | 2021-08-27 | Product for recovering diabetes and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113521277A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007330124A (en) * | 2006-06-13 | 2007-12-27 | Kenko Tsusho Kk | Health food composition for preventing and ameliorating obesity and lifestyle-related disease |
| US20080193603A1 (en) * | 2005-04-06 | 2008-08-14 | Hayes Kenneth C | Method and Composition for Nutritionally Improving Glucose Control and Insulin Action |
| US20120040014A1 (en) * | 2010-08-12 | 2012-02-16 | Robert Settineri | LIPID Supplements for Maintaining Health and Treatment of Acute and Chronic Disorders |
| US20130189298A1 (en) * | 2012-01-20 | 2013-07-25 | Guo-Jane Tsai | Novel yeast strain and the application thereof |
| CN107751387A (en) * | 2017-10-28 | 2018-03-06 | 卜球 | A kind of formula milk and its production method for helping to reduce blood sugar for human body |
-
2021
- 2021-08-27 CN CN202110998432.6A patent/CN113521277A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080193603A1 (en) * | 2005-04-06 | 2008-08-14 | Hayes Kenneth C | Method and Composition for Nutritionally Improving Glucose Control and Insulin Action |
| JP2007330124A (en) * | 2006-06-13 | 2007-12-27 | Kenko Tsusho Kk | Health food composition for preventing and ameliorating obesity and lifestyle-related disease |
| US20120040014A1 (en) * | 2010-08-12 | 2012-02-16 | Robert Settineri | LIPID Supplements for Maintaining Health and Treatment of Acute and Chronic Disorders |
| CN103200827A (en) * | 2010-08-12 | 2013-07-10 | 营养治疗公司 | Lipid supplements for maintaining health and the treatment of acute and chronic disorders |
| US20130189298A1 (en) * | 2012-01-20 | 2013-07-25 | Guo-Jane Tsai | Novel yeast strain and the application thereof |
| CN107751387A (en) * | 2017-10-28 | 2018-03-06 | 卜球 | A kind of formula milk and its production method for helping to reduce blood sugar for human body |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1389466B1 (en) | A dispersion on the basis of beta-glucan containing superfine particles, a corresponding process of manufacturing and the use of said dispersion | |
| CN111670997A (en) | Preparation method of immune-enhancing compound protein peptidase hydrolyzed liquid, immune-enhancing compound protein peptide beverage and preparation method thereof | |
| KR101390044B1 (en) | Visceral fat accumulation inhibitor, and agent for promoting the increase in and/or inhibiting the decrease in blood adiponectin level | |
| DE60200256T3 (en) | Basic protein fraction from milk as an active ingredient for the reduction of high blood pressure | |
| US20040234631A1 (en) | Composition comprising soy and use thereof in the provention and/or treatment of various diseases | |
| CN107890117A (en) | A kind of compound oligomeric peptide nutrient powder of WPC | |
| JP6093300B2 (en) | Composition for preventing and / or improving irreversible metabolic disorders associated with cancer | |
| DE2921852A1 (en) | LIPID LOWERING AGENT | |
| CN107441217A (en) | A kind of Orally taken emulsion rich in alpha linolenic acid and preparation method thereof | |
| DE602004000665T2 (en) | Biological process for producing a heme iron preparation and food products made therefrom | |
| CN113521277A (en) | Product for recovering diabetes and preparation method thereof | |
| DE60216523T2 (en) | PREPARATION AND USE OF SOY PROTEIN HYDROLYSATES ENRICHED WITH BRANCHED AMINO ACIDS | |
| CN111643392A (en) | Biological oligopeptide essence with multiple-effect whitening and anti-allergy effects and preparation method thereof | |
| US6288047B1 (en) | Lipid-based immune modulator composition | |
| KR101111390B1 (en) | The Functional Coffee Mixer comprising Tocoperol, VitaminC and Lecithin And Its Manufacturing Method | |
| RU2274003C2 (en) | Method for complex processing agricultural animals blood for preparing hemoglobin-base biologically active substance with anti-anemic properties, biologically active substance with anti-anemic properties (variants) and product comprising thereof (variants) | |
| DE60037197T2 (en) | USE OF FUNCTIONAL ORAL PREPARATIONS | |
| KR20220063699A (en) | Fermentation composition for promoting height growth comprising fermented oyster extract | |
| KR101241455B1 (en) | Bean curd having hypotensive effect | |
| JP2003012538A (en) | Antioxidant agent | |
| CN117337971B (en) | Composition containing pilose antler and preparation method and application thereof | |
| CN109010564A (en) | A kind of preparation method and application of the medical sweet potato leaf extract with effect for reducing blood fat | |
| JPWO2006008890A1 (en) | Muscle building composition | |
| US6787162B1 (en) | Method and composition for regulation of blood cholesterol | |
| US20220151275A1 (en) | Dietary Supplement for Gastrointestinal Inflammation and Method for Making the Same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |